This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon Announces Data Presentation At The 2012 American Urological Association Annual Meeting

May 21, 2012–Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Urological Association (AUA) Annual Meeting taking place May 19 – 23, 2012 in Atlanta, Georgia.
  • “Sipuleucel-T in African Americans: A Subgroup Analysis of Three Phase 3 Trials of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer,” abstract #953. Moderated Poster Session, Prostate Cancer: Advanced III from 10:30 a.m. to 12:30 p.m. ET on Monday, May 21, 2012.
  • “Estimating the Overall Survival Benefit of Sipuleucel-T in the IMPACT Trial Accounting for Crossover Treatment in Control Subjects with Autologous Immunotherapy Generated From Cyropreserved Cells,” abstract #683. Oral Presentation, Prostate Cancer: Advanced 1 Podium from 3:30 to 5:30 p.m. ET on Sunday, May 20, 2012.

“These data continue to support the overall survival benefit of PROVENGE, an important treatment option for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer,” said Mark Frohlich, MD, executive vice president and chief medical officer. “As shown in Phase 3 clinical trials, PROVENGE demonstrated an overall survival benefit and represents an important treatment option for men with advanced prostate cancer.”

Abstract #953: Sipuleucel-T in African Americans: A Subgroup Analysis of Three Phase 3 Trials of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer

This exploratory analysis evaluated the survival benefit associated with PROVENGE in the African American men who participated in the three PROVENGE Phase 3 studies, including the IMPACT trial. Among 737 patients with metastatic castrate resistant prostate cancer, 488 were randomized to receive PROVENGE (African American, 33; Caucasian, 437; other races, 18) and 249 were randomized to the control arm (African American, 10; Caucasian, 229; other races, 10). Cox proportional hazards regression analysis was used to assess the treatment effect on overall survival in all randomized patients and the African American subpopulation.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.21 -0.44%
FB $117.80 -0.22%
GOOG $701.26 0.80%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs